Vistagen Therapeutics Inc (VTGN) Position Increased by Sphera Funds Management LTD.

Sphera Funds Management LTD. increased its stake in Vistagen Therapeutics Inc (NASDAQ:VTGN) by 22.0% in the third quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 1,673,918 shares of the company’s stock after purchasing an additional 302,026 shares during the period. Sphera Funds Management LTD. owned 5.39% of Vistagen Therapeutics worth $2,427,000 as of its most recent filing with the Securities & Exchange Commission.

Shares of NASDAQ VTGN opened at $1.76 on Friday. Vistagen Therapeutics Inc has a 12 month low of $0.81 and a 12 month high of $2.44. The company has a market cap of $52.80 million, a price-to-earnings ratio of -1.59 and a beta of -1.58.

Vistagen Therapeutics (NASDAQ:VTGN) last announced its quarterly earnings data on Monday, October 29th. The company reported ($0.30) EPS for the quarter, missing the consensus estimate of ($0.17) by ($0.13). Equities research analysts predict that Vistagen Therapeutics Inc will post -1.1 earnings per share for the current year.

A number of analysts recently commented on the stock. Oppenheimer set a $6.00 target price on shares of Vistagen Therapeutics and gave the stock a “buy” rating in a research note on Sunday, November 4th. Maxim Group set a $6.00 target price on shares of Vistagen Therapeutics and gave the stock a “buy” rating in a research note on Wednesday, October 3rd. ValuEngine upgraded shares of Vistagen Therapeutics from a “hold” rating to a “buy” rating in a research note on Thursday, November 1st. Finally, Zacks Investment Research upgraded shares of Vistagen Therapeutics from a “hold” rating to a “buy” rating and set a $1.50 target price for the company in a research note on Thursday, August 30th. One research analyst has rated the stock with a sell rating and five have assigned a buy rating to the company. The stock presently has an average rating of “Buy” and an average target price of $8.30.

WARNING: This article was reported by American Banking News and is owned by of American Banking News. If you are accessing this article on another domain, it was illegally stolen and republished in violation of United States and international trademark and copyright laws. The original version of this article can be accessed at https://www.americanbankingnews.com/2018/12/08/vistagen-therapeutics-inc-vtgn-position-increased-by-sphera-funds-management-ltd.html.

About Vistagen Therapeutics

VistaGen Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in developing and commercializing medicines for depression and other central nervous system (CNS) disorders. The company's lead product candidate is AV-101, which is in Phase II development stage, an adjunctive treatment used for major depressive disorder.

See Also: How Do I Invest in Dividend Stocks

Receive News & Ratings for Vistagen Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vistagen Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply